Skip to main content
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG — Investor Relations & Filings

Ticker · CRSP ISIN · CH0334081137 LEI · 506700O6IRRIQLT3W370 US Manufacturing
Open in API
Filings indexed 823 across all filing types
Latest filing 2016-10-20 Director's Dealing
Country CH Switzerland
Listing US CRSP

About CRISPR Therapeutics AG

https://crisprtx.com/

CRISPR Therapeutics AG is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company leverages this technology to make precise, directed changes to genomic DNA. As a pioneer in the field, CRISPR Therapeutics has established a diverse portfolio of therapeutic programs across several disease areas, including hemoglobinopathies (such as sickle cell disease and beta-thalassemia), immuno-oncology, regenerative medicine, and cardiovascular disease. The company was one of the first to advance a CRISPR-based therapy into clinical trials and receive regulatory approval, aiming to create potentially curative treatments for patients.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2016-10-20 English
FORM 4 SUBMISSION
Director's Dealing
2016-10-20 English
FORM S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as stock option plans and employee stock purchase plans. It includes detailed information about stock option plans, registration fees, indemnification of directors and officers, and references to other filings. This type of filing is related to share issuance and capital changes, specifically for employee stock plans. It is not an annual report, earnings release, or any other financial report but a registration statement for securities issuance under employee plans. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the actual registration statement, not just an announcement or certification.
2016-10-20 English
424B4
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus for an initial public offering (IPO) of common shares by CRISPR Therapeutics AG. It includes extensive information typical of an IPO prospectus such as offering details, risk factors, use of proceeds, management discussion, financial data, and business overview. The presence of the SEC filing form type '424B4' and the detailed offering information confirms this is a registration/prospectus document related to capital raising. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or a brief summary, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2016-10-19 English
Regulatory Filings 2016
Regulatory Filings
2016-10-19 English
FORM 3 SUBMISSION
Director's Dealing
2016-10-19 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.